Hansa Biopharma at a Glance
Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.
The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.
Hansa’s research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.
Discovery of imlifidase
SVP, Chief Scientific Officer and Chief Operating Officer
The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Dialogue with the Food and Drug Administration regarding a regulatory path for the U.S. market.
Approximately 200,000 patients in Europe and the U.S. are waiting for a kidney transplant. 30,000 of them are classified as highly sensitized.
Proprietary technology platform with imliﬁdase and 2nd generation enzymes. Signiﬁcant patent protection beyond 2035 based on a possibility of up to ﬁve years extension.
Existing collaborations with leading research clinics. Growing number of partnerships with industry, healthcare and academia.
Clinical studies on imlifidase in rare acute autoimmune conditions. Next generation IgG-cleaving enzymes for repeat dosing.
Focus on developing innovative lifesaving and life altering therapies in rare diseases with signiﬁcant unmet medical need.
Innovative biopharmaceutical company, with 90+ employees, Headquarter in Lund, Sweden and also has operations in other European countries and in the U.S.
Hansa is growing rapidly and expanding reach and focus. There are golden opportunities for highly talented, skilled, and passionate people.
Our Business Model
Hansa Biopharma is currently establishing a commercial organization to become a fully integrated biopharma company. If we receive the necessary marketing authorization we will go to market in Europe and the U.S. with our own organization and build a foundation for independent and sustainable growth. We will seek commercial partnerships for markets outside these regions. We will continue to invest in R&D in the areas of rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, cancer and neutralizing antibodies in gene therapy. We seek strategic partnerships and look for out-licensing opportunities in areas beyond our primary focus and outside our core business region.